Botulinum Toxin Type A in the Treatment of Dermatochalasis: An Open-Label, Randomized, Dose-Comparison Study

July 2006 | Volume 5 | Issue 7 | Original Article | 596 | Copyright © July 2006

Joel L. Cohen MD, Steven H. Dayan MD FACS

Objective: To compare the efficacy and safety of 2 doses of botulinum toxin type A in the treatment of dermatochalasis. Methods: Forty patients with mild to moderate dermatochalasis were randomly assigned to receive 1 of 2 doses of botulinum toxin type A in the lateral infrabrow—4 U/brow or 6 U/brow—and followed up for 20 weeks. Results: Investigator assessment showed the proportion of responders (?1 grade improvement in severity of dermatochalasis on a scale of none, mild, moderate, or severe) at week 2 was 32% with 4 U and 47% with 6 U. Compared with the lower dose group, the higher dose group also reported a greater degree of improvement, significantly higher ratings for feelings of attractiveness and feelings of satisfaction with appearance, and a higher incidence of satisfaction. Conclusion: Single-site injection of botulinum toxin type A in the lateral infrabrow can offer effective treatment for mild to moderate upper eyelid dermatochalasis.